🇺🇸 FDA
Patent

US 12213998

Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease

granted A61KA61K35/28A61K35/35

Quick answer

US patent 12213998 (Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease) held by Takeda Pharmaceutical Company Limited expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K35/28, A61K35/35, A61P, A61P1/00